ReNerve

ASX Announcement

14 October 2025

ReNerve achieves first sales of amniotic tissue range

- First commercial sale achieved for ReNerve's EmpliQ™ amniotic tissue products
- EmpliQ™ range showcased at the ASSH annual meeting in Vancouver, featuring three minimally processed products designed to support faster post-surgical recovery
- Complementary to ReNerve's NervAlign® range, the EmpliQ™ products can be used in wound management associated with peripheral nerve repair and broader applications such as diabetic ulcers
- With regulatory clearance in the US and aligned with ReNerve's existing distribution channels, the EmpliQ™ range is positioned to drive ongoing revenue growth

ReNerve Limited (ASX, "ReNerve" or "the Company"), a pioneering Australian medical device company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to announce that it has achieved the first sale of its EmpliQ amniotic tissue products.

ReNerve has three products in the range, which the company featured at the recent American Society for Surgery of the Hand (ASSH) annual meeting in Vancouver, Canada. The amniotic tissue is minimally processed and used in the treatment of wounds as the endogenous growth factors and cytokines aid a faster recovery post-surgery.

The EmpliQ amniotic range is complementary to the Company's NervAlign® product range and can be used in the treatment of wounds associated with peripheral nerve repairs. The three products in the EmpliQ range are each designed to assist with the recovery of all wounds, from surgical wounds through to diabetic ulcers.

"This is another positive step forward for ReNerve after several extremely busy recent months for the company. Getting the EmpliQ range into the market is an important part of our overall strategy as we take ReNerve from a pure R&D focused business into commercial activities," said CEO Dr Julian Chick.

"These products have regulatory clearance in the major US market, and are well suited to our existing sales and distribution channels. We expect the EmpliQ range to continue expanding revenue growth for ReNerve."

ReNerve announced a strategic partnership with Berkeley Biologics LLC for the new deep dermal and amniotic tissue-based product ranges on 2 June 2025. ReNerve is leveraging its eCOO technology, already proven through its NervAlign® Nerve Cuff, to develop and bring to market a range of nerve conduit products. ReNerve is also progressing the development of its proprietary nerve guide matrix, aimed at the treatment of more severe nerve injuries. The global market for peripheral nerve repair is estimated to be around USD$1.6 billion and growing at 17+%. The global dermal and amniotic tissue market is estimated to be worth around USD$2.7 billion in 2024 and growing at around 12% CAGR[1], with these products used in a range of applications.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

[1] MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.96 billion in 2024 and is projected to reach $6.2 billion by 2031.[2]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[2] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)